Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring health care information both rapidly and directly to the consumer or healthcare provider. CEO, Ray Akers, features some of company's proprietary testing products, including diabetes complication and lung cancer diagnostics. Growth is derived from global strategic partnerships and distributors like Cardinal Health, Thermo Fisher and Medline. AKER is now trading for more than cash and Akers believes is it a great value and time for investors to look at the company due to rapid sales trends and product commercialization. Jill Malandrino reports from the NASDAQ Market Site in New York.

If you liked this article you might like

5 Stocks Under $10 Set to Soar

4 Stocks Under $10 to Trade for Big Breakouts

3 Health Services Stocks Moving The Industry Upward

3 Stocks Raising The Health Services Industry Higher

3 Stocks Advancing The Health Care Sector